A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

NCT04622046 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Symptomatic Transthyretin Amyloid Cardiomyopathy

Interventions

DRUG: ALXN2060

Sponsor

Alexion Pharmaceuticals, Inc.

Collaborators

[object Object]